Does CytoSorb Interfere with Immunosuppression? A Pharmacokinetic and Functional Evaluation [PDF]
PharmaceuticsBackground/Objectives: Cytokine release during organ transplantation contributes to primary graft dysfunction and requires careful immunomodulation. CytoSorb, a hemoadsorption device developed to reduce circulating cytokine levels, is increasingly used ...
Stephan Harm +4 more
doaj +5 more sources
The use of CytoSorb hemoadsorption in critically ill patients: a narrative review [PDF]
Frontiers in MedicineInflammation, a complex biological response against injury or infection, is an important pathological basis for various critical diseases. A “normal” immune response exemplifies a balanced dialogue between immunological cells and a medley of pro- and ...
Kaixin Lei +7 more
doaj +6 more sources
Biomedicines, 2020 Septic shock is a major burden to healthcare with mortality rates remaining high. Blood purification techniques aim to reduce cytokine levels and resultant organ failure.
Christopher Rugg +2 more
exaly +4 more sources
Impact of CytoSorb® on interleukin-6 in cardiac surgery
Frontiers in Cardiovascular Medicine, 2023 ObjectiveCardiac surgery is known to activate a cascade of inflammatory mediators leading to a systemic inflammatory response. Hemadsorption (HA) devices such as CytoSorb® have been postulated to mitigate an overshooting immune response, which is ...
Daniela Geisler, Thomas Aschacher
exaly +5 more sources
Antibiotics and Other Drugs Removal by the CytoSorb® Haemoadsorber: A Systematic Review of Available Evidence [PDF]
AntibioticsBackground/Objectives: Haemoadsorption has recently emerged as an extracorporeal treatment option for sepsis, septic shock, intoxications, and cardiac surgery to modulate dysregulated inflammatory responses or remove a wide range of circulating molecules.
Sara Kenda, Jakob Gubenšek, Tomaž Vovk
doaj +2 more sources
CytoSorb in patients with coronavirus disease 2019: A rapid evidence review and meta-analysis
Frontiers in Immunology, 2023 BackgroundAfter its approval by the European Union in 2011, CytoSorb therapy has been applied to control cytokine storm and lower the increased levels of cytokines and other inflammatory mediators in blood.
Mingming Li, Yongnan Li
exaly +3 more sources
Early impact of CytoSorb® adsorber on proinflammatory cytokine plasmatic levels in a porcine model of refractory cardiogenic shock supported with VA-ECMO [PDF]
BMC Cardiovascular DisordersBackground Cardiogenic shock (CS) is a pejorative situation which often requires a circulatory support with VA-ECMO. However, VA-ECMO is known to trigger an inflammatory cascade with expression of proinflammatory cytokines Interleukin-6 (IL-6) and ...
Juliette Piccoli +9 more
doaj +2 more sources
Frontiers in Medicine, 2021 Introduction: CytoSorb extracorporeal blood purification therapy received FDA Emergency Use Authorization (EUA) to suppress hyperinflammation in critically ill COVID-19 patients.
Lucian Durham +2 more
exaly +3 more sources
CytoSorb® Hemadsorption During Microaxial Flow Pump (mAFP) Support in Cardiogenic Shock: A Propensity Score-Matched Cohort Study [PDF]
BiomedicinesBackground: Despite advances in temporary mechanical circulatory support (tMCS), patients with cardiogenic shock (CS) who are treated with a microaxial flow pump (mAFP; Impella®, Abiomed) still have a high mortality rate.
Julian Kreutz +7 more
doaj +2 more sources
Case Report: CytoSorb hemoadsorption as an adjunctive therapy in critically ill pregnant women with COVID-19 and acute kidney injury—a case series [PDF]
Frontiers in MedicinePurposeCritically ill pregnant women with COVID-19 are at high risk for acute kidney injury (AKI) and a hyperinflammatory state, contributing to multiorgan failure.
Minoo Heidari Almasi +5 more
doaj +2 more sources